comparemela.com
Home
Live Updates
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants : comparemela.com
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
Design of the multi-center study is based on Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD), a condition for which there are
Related Keywords
Japan ,
Diego Ardig ,
Hill Bio ,
Development Head At Chiesi Group ,
Chiesi Group ,
National Institute Of Child Health ,
Human Development ,
Oak Hill ,
Victoria Niklas ,
Chief Medical Officer ,
Oak Hill Bio ,
Development Head ,
National Institute ,
Child Health ,
comparemela.com © 2020. All Rights Reserved.